1. Alkermes reports Q2 revenues at $390.7 million. 2. GAAP net income stands at $87.1 million, down from 2024. 3. Positive results from Vibrance-1 study of alixorexton announced. 4. Company reaffirms 2025 financial expectations amidst solid products performance. 5. LYBALVI and ARISTADA show significant revenue growth compared to 2024.
Strong revenue performance and positive research results boost investor confidence, potentially increasing stock value. Historical context shows similar product announcements led to significant price increases.
The article highlights strong financials and product potential, which are critical for investor sentiment. Successful clinical outcomes can lead to increased future revenues and stock performance.
Positive trial results and sustained revenue growth suggest a strong future outlook for ALKS. Long-term growth is backed by ongoing advancements in product offerings.
DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2025.
"Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive topline results from Vibrance-1, our phase 2 study of alixorexton (ALKS 2680) in narcolepsy type 1, were an important milestone in the development program and underscore the differentiated features of alixorexton. These data also highlight the potential of orexin 2 receptor agonists to transform the treatment of narcolepsy. As we prepare to initiate a global phase 3 program, we look forward to sharing detailed results from Vibrance-1 at the upcoming World Sleep Congress and topline results from our Vibrance-2 study in patients with narcolepsy type 2 this fall."
(In millions)
(In millions)
(In millions)
At June 30, 2025, the company recorded cash, cash equivalents and total investments of $1.05 billion, compared to $916.2 million at March 31, 2025.
Alkermes reiterates its financial expectations for 2025, as set forth in its press release dated Feb. 12, 2025.
Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA...
Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995...
For Investors: Sandy Coombs +1 781 609 6377
For Media: Katie Joyce +1 781 249 8927